Okechukwu Obulezi | Blood Cancer | Best Paper Award

Published on by Oncology

Dr. Okechukwu Obulezi | Blood Cancer | Best Paper Award 

Lecturer | Nnamdi Azikiwe Univeristy | Nigeria

Dr. Okechukwu Jeremiah Obulezi, Ph.D., is a distinguished statistician whose academic trajectory, research productivity, and multidisciplinary impact make him exceptionally suitable for a Best Paper Award. With a strong foundation in Statistics from Nnamdi Azikiwe University and Abia State Polytechnic, culminating in a Ph.D. focused on developing innovative generalized distribution families through Logistic-X transformations, he has consistently advanced statistical theory and its applications. His research interests span probability distributions, machine learning models, survival analysis, competing risks, acceptance sampling, optimum sampling, mask data and censoring schemes—areas crucial to modern data-driven decision-making in engineering, biomedical sciences, public health, and socio-economic modelling. Dr. Obulezi’s publication record is extensive and impactful, with over forty peer-reviewed journal articles in reputable outlets such as Heliyon, Scientific African, Alexandria Engineering Journal, Entropy, Symmetry, AIP Advances, and Earthline Journal of Mathematical Sciences. His works introduce new probability distributions, propose enhanced estimation techniques, develop sampling plans, and apply machine learning to real-world problems such as financial volatility, disease survival modelling, COVID-19 mortality, rainfall analysis, transportation cost prediction, and biomedical datasets. His methodological sophistication and ability to translate theory into practical applications underscore his scholarly depth. Professionally, he serves as Lecturer I at Nnamdi Azikiwe University and holds several academic leadership roles, including Seminar & Project Coordinator and member of multiple university committees. His international academic influence is further demonstrated through active service as a reviewer for renowned journals under Springer, Elsevier, Taylor & Francis, and Scopus-indexed platforms. Dr. Obulezi’s conference contributions and book chapter reviews further affirm his commitment to advancing statistical knowledge. Collectively, his robust research output, innovative contributions to distribution theory, interdisciplinary relevance, and sustained scholarly engagement establish him as a highly deserving candidate for the Best Paper Award.

Profile: Google Scholar 

Featured Publications

  1. Onyekwere, C. K., & Obulezi, O. J. (2022). Chris-Jerry distribution and its applications. Asian Journal of Probability and Statistics, 20(1), 16–30.

  2. Chinedu, E. C. Q., Chukwudum, Q. C., Alsadat, N., Obulezi, O. J., Almetwally, E. M., & Others. (2023). New lifetime distribution with applications to single acceptance sampling plan and scenarios of increasing hazard rates. Symmetry, 15(10), 1–33.

  3. Orji, G. O., Etaga, H. O., Almetwally, E. M., Igbokwe, C. P., Aguwa, O. C., & Obulezi, O. J. (2025). A new odd reparameterized exponential transformed-X family of distributions with applications to public health data. Innovation in Statistics and Probability, 1(1), 88–118.

  4. Obulezi, O. J., Anabike, I. C., Oyo, O. G., Harrison, E., & Perpetua, I. C. (2023). Marshall-Olkin Chris-Jerry distribution and its applications. International Journal of Innovative Science and Research Technology, 8(5), 1–15.

  5. Anabike, I. C., Igbokwe, C. P., Onyekwere, C. K., & Obulezi, O. J. (2023). Inference on the parameters of Zubair-Exponential distribution with application to survival times of guinea pigs. Journal of Advances in Mathematics and Computer Science, 38(7), 12–35.

By creating forward-looking statistical frameworks with real-world applications, the nominee’s research bridges science and society, enabling smarter policies, stronger industries, and transformative technological progress.

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Ping Dai | Cancer Therapy | Best Researcher Award

Published on by Oncology

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024